OXON Epidemiology

OXON Epidemiology is a full-service scientific Contract Research Organization (CRO) specialising in generating Real-World Evidence (RWE) for pre- and post-approval products via strategic, scientific and operational solutions to the biopharmaceutical and medical device industries.

Based in London, Madrid and the USA, OXON offers a full spectrum of RWE solutions in the areas of Safety, HEOR/Market Access, Drug development and Marketing via:

• Multi-country field, chart review and database epidemiological studies
• Patient registries
• Risk management, PASS and Risk minimisation studies
• Statistical signal detection & analysis
• Quantitative benefit-risk analysis for CTD / PBRER
• Patient-reported outcomes
• Health economics & modelling
• Meta-analysis
• Evidence strategy

We have an international network of clinical and world-renowned academic consultants, being among OXON staff publications: Lancet (x11), NEJM (x2), JAMA (x1) and BMJ (x4).

OXON is an ENCePP centre (European Network of Centres in Pharmacoepidemiology and Pharmacovigilance) of the EMA (European Medicines Agency), where we are leading an initiative on data integration with EMA regulators and leading academic pharmacoepidemiologists.

Our collaborative approach—partnering with academic institutions and clients—combined with our extensive expertise in observational studies, patient registries, and complex study designs, ensures the highest level of scientific rigor and impactful results. This positions us as a trusted partner for companies worldwide seeking meaningful real-world evidence (RWE) that meets regulatory standards and informs critical healthcare decision-making.

MARCAS: OXON EPIDEMIOLOGY